The Canadian government has announced C$67 million in new investments to strengthen the country's life sciences sector and improve health security.

Announced on September 18, 2026, the funding will support five projects focused on technologies with potential applications in health care, emergency preparedness and domestic manufacturing.

Among the projects, Applied Pharmaceutical Innovation in Alberta will receive up to C$21.9 million to develop a Canadian antimicrobial supply-resilience initiative. The project aims to strengthen access to antibiotics and other antimicrobial medicines.

In British Columbia, Avivo Biomedical will receive up to C$10.9 million for technology designed to convert different blood types into Type O, potentially expanding options for blood transfusions and organ transplantation.

The investment also includes funding for Northern RNA, Qidni Labs and STEMCELL Technologies, covering RNA manufacturing, portable hemodialysis and domestic cell-culture media production.

The government is also providing C$2.2 million to establish the Canadian Drug Supply Observatory, a national hub intended to monitor and respond to drug shortages.

The projects form part of Canada's broader effort to strengthen health-care innovation, domestic biomanufacturing and health-system resilience.